European heart journal · 2026
Gut microbe-generated metabolite trimethylamine N-oxide and risk of abdominal aortic aneurysm: a cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Xinmin S, Wang Meng, Wang Zeneng, Fan Bingbing, Tian Melissa Y, Filippazzo Jesse, Lee Yujin, Mallela Deepthi P, Mao Karis, Liu Yang, Lemaitre Rozenn N, Xie Victor, Diaz Emilia, DiDonato Joseph A, Tang W H Wilson, de Oliveira Otto Marcia C, Budoff Matthew J, Owens A Phillip, Newman Anne B, Cameron Scott J, Siscovick David S, Lusis Aldons J, Mozaffarian Dariush, Hazen Stanley L
Аннотация
BACKGROUND AND AIMS: Abdominal aortic aneurysms (AAAs) are associated with increased mortality in older adults. The gut microbe-generated metabolite trimethylamine N-oxide (TMAO) has been linked to AAA risk and promotes AAA progression in animal models. Whether circulating TMAO levels in apparently healthy older adults predict AAA development and adverse AAA outcomes remains unknown.
METHODS: Plasma TMAO levels were quantified using stable isotope dilution liquid chromatography-tandem mass spectrometry in 4442 community-dwelling adults (aged ≥65 years) in the Cardiovascular Health Study. Participants underwent ultrasound screening and prospective follow-up. Multivariable models assessed associations of serial TMAO levels with AAA development and incident risk for adverse AAA events, adjusting for traditional risk factors, renal function, socioeconomic status, and cardiometabolic lifestyle factors.
RESULTS: Higher baseline TMAO levels were associated with larger infrarenal aortic diameter and increased AAA risk. Over a median 12.2-year follow-up (54 402 person-years), 79 participants experienced incident adverse AAA events (repair, rupture, or AAA-related death). Elevated TMAO levels were independently associated with higher risk of adverse AAA events, whether modelled continuously [adjusted hazard ratio (HR) 1.28, 95% confidence interval (CI) 1.07-1.54 per doubling], by quantiles (HR for tertile 3 vs tertile 1: 2.46, 95% CI 1.32-4.59), or using a clinical threshold (≥6.2 µM; HR 1.93, 95% CI 1.25-2.99).
CONCLUSIONS: In community-based older adults, higher TMAO levels were independently associated with increased risk of AAA development and adverse AAA events. Findings support TMAO as a novel risk factor for AAA and a potential therapeutic target for AAA prevention.
METHODS: Plasma TMAO levels were quantified using stable isotope dilution liquid chromatography-tandem mass spectrometry in 4442 community-dwelling adults (aged ≥65 years) in the Cardiovascular Health Study. Participants underwent ultrasound screening and prospective follow-up. Multivariable models assessed associations of serial TMAO levels with AAA development and incident risk for adverse AAA events, adjusting for traditional risk factors, renal function, socioeconomic status, and cardiometabolic lifestyle factors.
RESULTS: Higher baseline TMAO levels were associated with larger infrarenal aortic diameter and increased AAA risk. Over a median 12.2-year follow-up (54 402 person-years), 79 participants experienced incident adverse AAA events (repair, rupture, or AAA-related death). Elevated TMAO levels were independently associated with higher risk of adverse AAA events, whether modelled continuously [adjusted hazard ratio (HR) 1.28, 95% confidence interval (CI) 1.07-1.54 per doubling], by quantiles (HR for tertile 3 vs tertile 1: 2.46, 95% CI 1.32-4.59), or using a clinical threshold (≥6.2 µM; HR 1.93, 95% CI 1.25-2.99).
CONCLUSIONS: In community-based older adults, higher TMAO levels were independently associated with increased risk of AAA development and adverse AAA events. Findings support TMAO as a novel risk factor for AAA and a potential therapeutic target for AAA prevention.